Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9966557 | 0.98 | AKR1C1 (0.68) | AKR1C1HDAC1HDAC4MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL28915897 | 0.96 | AKR1C1 (0.66) | AKR1C1HDAC1HDAC4MEN1KMT2A | |
| SCHEMBL1492737 | 0.94 | AKR1C1 (0.62) | AKR1C1HDAC1HDAC4MEN1KMT2A | |
| SCHEMBL2221 | 0.90 | AKR1C1 (0.55) | AKR1C1HDAC1MEN1KMT2ATSHR | |
| SCHEMBL3910628 | 0.88 | AKR1C1 (0.53) | AKR1C1HDAC1MEN1KMT2ATSHR | |
| Water SCHEMBL3910626 | 0.86 | AKR1C1 (0.52) | AKR1C1HDAC1MEN1KMT2ATSHR | |
| SCHEMBL4770404 | 0.84 | HDAC1 (0.53) | AKR1C1HDAC1HDAC4MEN1KMT2A | |
| SCHEMBL14790445 | 0.83 | HDAC1 (0.51) | AKR1C1HDAC1HDAC4MEN1KMT2A | |
| SCHEMBL29604970 | 0.83 | LMNA (0.55) | AKR1C1HDAC1HDAC4MEN1KMT2A | |
| SCHEMBL4804303 | 0.83 | HDAC1 (0.51) | AKR1C1HDAC1HDAC4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12521395-B2 | Gem-disubstituted heterocyclic compounds and their use as IDH inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2026-01-13 | — | — | US | disclosed |
| EP-4055015-B1 | GEM-DISUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IDH INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2025-04-02 | — | — | EP | disclosed |
| US-20230000871-A1 | GEM-DISUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IDH INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-01-05 | — | — | US | disclosed |
| US-20230000871-A1 | GEM-DISUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IDH INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-01-05 | — | — | US | disclosed |
| EP-4055015-A1 | GEM-DISUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IDH INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2022-09-14 | — | — | EP | disclosed |
| CN-115038700-A | Gem disubstituted heterocyclic compounds and their use as IDH inhibitors | 内尔维亚诺医疗科学公司 | 2022-09-09 | — | — | CN | disclosed |
| US-11274100-B2 | EP300/CREBBP inhibitor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-03-15 | — | — | US | disclosed |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
| EP-3643703-A1 | EP300/CREBBP INHIBITOR | Daiichi Sankyo Co., Ltd. (JP) | 2020-04-29 | — | — | EP | disclosed |
| EP-3643703-A1 | EP300/CREBBP INHIBITOR | Daiichi Sankyo Co., Ltd. (JP) | 2020-04-29 | — | — | EP | disclosed |
| US-20120322795-A1 | BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
| WO-2012082817-A1 | BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | WO | disclosed |
| US-20110237849-A1 | LIQUID CRYSTAL COMPOUNDS AND METHOD FOR PREPARING THE SAME | Dongjin Semichem Co., Ltd., (KR) | 2011-09-29 | — | — | US | disclosed |
| WO-2010071335-A1 | LIQUID CRYSTAL COMPOUNDS AND METHOD FOR PREPARING THE SAME | DONGJIN SEMICHEM CO., LTD. (KR) | 2010-06-24 | — | — | WO | disclosed |
| US-7465719-B2 | Carbamic acid compounds comprising an ester or ketone linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2008-12-16 | — | — | US | disclosed |
| US-7465719-B2 | Carbamic acid compounds comprising an ester or ketone linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2008-12-16 | — | — | US | disclosed |
| US-7465719-B2 | Carbamic acid compounds comprising an ester or ketone linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2008-12-16 | — | — | US | disclosed |
| US-20060058282-A1 | Carbamic acid compounds comprising an ester or ketone linkage as hdac inhibitors | TOPOTARGET UK LIMITED (GB) | 2006-03-16 | — | — | US | disclosed |
| EP-1583736-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN ESTER OR KETONE LINKAGE AS HDAC INHIBITORS | TopoTarget UK Limited (GB) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004065354-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN ESTER OR KETONE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274100-B2 | EP300/CREBBP inhibitor | EP300, CREBBP, CREB1 | AKR1C1 2816/4885HDAC1 6/4885HDAC4 25/4885 |
| US-20060058282-A1 | Carbamic acid compounds comprising an ester or ketone linkage as hdac inhibitors | HDAC1, HDAC7, HDAC11 | AKR1C1 211/4885HDAC1 1/4885HDAC4 9/4885 |
| US-20110237849-A1 | LIQUID CRYSTAL COMPOUNDS AND METHOD FOR PREPARING THE SAME | HCK, NLK, VRK1 | AKR1C1 2328/4885HDAC1 3874/4885HDAC4 4287/4885 |
| US-20120322795-A1 | BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTB4R, LTB4R2, LTC4S | AKR1C1 145/4885HDAC1 1448/4885HDAC4 3139/4885 |
| US-20230000871-A1 | GEM-DISUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IDH INHIBITORS | IDH1, IDH2, IDH3A | AKR1C1 1094/4885HDAC1 129/4885HDAC4 1135/4885 |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | EP300, CREBBP, CREB1 | AKR1C1 2816/4885HDAC1 6/4885HDAC4 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.